Paige, a digital pathology company, has added new research-use-only software to its eponymous Breast Suite. This AI-powered tool will help researchers discover signs of breast cancer metastasization in lymph nodes. Given the relatively large area of tissue under examination in these cases, pinpointing clumps of obtrusive tumor cells can be a tedious undertaking for pathologists. Paige’s innovation works in conjunction with their own interpretation of a sample, increasing the accuracy and efficacy of spotting potential tumors—including hard-to-notice micrometastases. Early identification of cancer cells from the breast spreading to the lymphatic system can greatly improve patient outcomes.
The AI at the center of the new pathology module also powers the company’s Paige Prostate, which earned FDA approval last September for analyzing a wide range of pathology data collated from various imaging scanners and slide-staining techniques. “This product launch is an important step in our overall commercialization strategy as we bring the power of our AI platform to new disease areas,” said Paige CEO Andy Moye.
February saw the company strike up two distribution partnerships. Pathology AI developer Mindpeak’s BreastIHC software, which detects, classifies, and tallies breast cancer cells, is now backed by Paige’s platform. An immuno-oncology deal with Flagship Biosciences will afford the same distribution leverage for the Colorado-based company’s software quantifying PD-L1 expression in immunohistochemistry tissue samples.
